TY - JOUR T1 - Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/1393003.congress-2017.PA4512 VL - 50 IS - suppl 61 SP - PA4512 AU - Miguel Angel Hernandez AU - Alexis Morales Boscan AU - Vanesa Hidalgo Sierra AU - Marco López Zubizarreta AU - Rosa Cordovilla Pérez AU - Soraya Jodra Sánchez AU - Miguel Barrueco Ferrero AU - Jose Maria Gonzalez Ruiz AU - Virginia Guevara VeláZquez Y1 - 2017/09/01 UR - http://erj.ersjournals.com/content/50/suppl_61/PA4512.abstract N2 - COPD exacerbations have negative impact in lung function and disease prognosis. Streptococcus pneumoniae is an important cause of exacerbation. Conjugate vaccine (PCV13) improves immune response against pneumococcus, and is useful to prevent pneumonias and invasive pneumococcal disease.Objetive: The objective of this study is to assess the clinical effectiveness of VNC 13 in the prevention of EPOC exacerbations.Matherial and Methods: We recruited 106 COPD patients in which PCV13 vaccination was recommended. Patients were followed for 3 years. We measured COPD exacerbations in vaccinated (82 patients; 77.3%) and not vaccinated (24 patients; 22.7%) which were considered as control group. For data analysis we applied Wilcoxon test (non-parametric data) with a confidence interval of 95% (p≤0.05). SPSS software was used to code and analyse data. All patients were vaccinated and treated according to clinical practice guides.Results: PCV13 significantly reduced moderate exacerbations of COPD in the third year after vaccination and severe exacerbations from the first year after vaccination. In the other groups exacerbations rate was also lower in the PCV13 vaccinated group, although statistical significance was not reached (see figure 1).Conclusions: In COPD patients, PCV13 could reduce moderate and severe exacerbations and consequently improve disease prognosis and reduce health spending. Studies with larger samples are needed to confirm these data and to determine which subgroups benefit more clearly from this therapeutic strategy. ER -